Intranasal influenza vaccine spurs strong immune response in Phase 1 study

Psychological distress high among students during COVID-19
3 February 2021
The quick choice might be a choice-overload avoidance strategy
3 February 2021

Intranasal influenza vaccine spurs strong immune response in Phase 1 study

An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation. The investigational vaccine, called Ad4-H5-VTN, is a recombinant, replicating adenovirus vaccine designed to spur antibodies to hemagglutinin, a protein found on the surface of influenza viruses that attaches to human cells.

Comments are closed.